Abridge
Abridge’s award-winning AI platform converts medical conversations into structured clinical notes that integrate directly into electronic health records.
Secondary Market Price
Secondary Market Price
Secondary Market Price Chart
Explore the latest data on a curated list of the top 2% of VC-backed companies in the US. Create a free account to unlock real-time secondary market prices.
Sign up to Unlock the Latest DataProspect Projected Future Abridge Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Abridge's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Abridge is deploying an enterprise-grade, AI-powered platform that transforms conversations between clinicians and patients into structured clinical notes in real time. The technology integrates directly with electronic medical records (EMR) and is used by more than 150 health system partners to reduce administrative burdens on providers. Founded in 2018, the company was established by a team that includes practicing cardiologist Shivdev Rao and AI scientist Zachary Lipton, with the goal of bringing more context and understanding to medical conversations. Originally known as intelligible.ai, Abridge is headquartered in Pittsburgh and has expanded with offices in San Francisco and New York City.
Looking forward, Abridge is focused on scaling its platform and expanding its capabilities, such as the real-time prior authorization feature recently launched with Highmark Health and Allegheny Health Network. This tool is designed to generate approvals for covered treatments directly at the point of conversation. The company's recent partnership with NYU Langone Health will see its technology used to support new facility designs, including exam rooms without computers. This momentum is bolstered by recent accolades, including being named to the Forbes Cloud 100 list for the second consecutive year and the Fierce Healthcare 2025 Fierce 50 Innovator list. The platform's real-world impact is demonstrated in collaborations like the one with Corewell Health, where its deployment led to a measurable reduction of 1.69 fewer hours of after-hours documentation time per provider.
- Andreessen Horowitz
- Khosla
- Bessemer
- IVP
- Redpoint
- Spark
- SV Angel
- Elad Gil
- CapitalG
- CVS Health
- Co-Founder, CEO Shivdev Rao
- Co-Founder, Sandeep Konam
- Co-Founder, CTO Zachary Lipton
- Co-Founder, Florian Metze
Peer Group Comparison
Vs Peer Group of >$4B Startups
How Abridge Measures Up
To help you manage your Abridge equity, Prospect has run the company through our machine learning model.
Prospect Rating
3x
Our 3x rating for Abridge reflects our projection that the company will be worth at least three times its current value in four years. For an employee with equity, this suggests the value of their stock could see a similar increase over that period.
Exit Risk
Low Risk
Our Low Risk rating for Abridge is based on the company being backed by top investors, which suggests a greater likelihood of reaching a liquidity event for employees compared to other startups.
Funding Stage
Funding
Since Abridge has secured significant funding, the company is poised for serious growth and has the stability to back it up. For you, this means you'll have the resources to make a real impact and ample opportunity to grow your career as the company expands.
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Abridge worth joining?
Abridge shows strong signs of a high-potential startup, with a recent valuation of $2.75 billion and total funding between $400-700M. To make a fully informed decision, you can use a platform like Prospect, which uses VC-grade data to evaluate and identify top-tier startups.
What should I do with my Abridge stock?
Since Abridge is a private company, managing your stock involves complex decisions around taxes, timing, and potential liquidity events. Platforms like Prospect offer tools to model different financial scenarios and create tax-optimized strategies for your equity.
Can you sell Abridge stock?
Selling stock in a private company like Abridge may be possible on secondary markets, but transactions are typically subject to company policies and transfer restrictions. Tools that provide access to secondary market data can help you understand the potential for such sales and navigate the process.
How can I find the value of my Abridge stock?
A stock's value can be estimated based on the company's most recent valuation, which is $2.75B for Abridge, and its total number of outstanding shares. For a more personalized projection, equity management platforms use predictive models to help you understand your holdings' potential worth.
What is Abridge's equity worth?
As a whole, Abridge's equity was last valued at $2.75 billion, a figure that reflects its significant growth and investor confidence. To determine what your specific grant could be worth, you can use data-driven platforms that model private company equity based on performance and market data.
What is Abridge's stock ticker symbol?
Abridge does not have a stock ticker symbol because it is a private company whose shares are not traded on public stock exchanges. Ticker symbols are only assigned to companies after they complete an Initial Public Offering (IPO).
Can I buy or sell Abridge stock?
As a private company, Abridge stock is not available on public markets, and buying it is generally limited to accredited investors during specific funding rounds. Selling shares may be possible through secondary markets, but this is typically subject to company approval and requires finding a private buyer.
What is the criteria to buy or invest in Abridge stock?
Investing in a private startup like Abridge is typically restricted to accredited investors who participate in organized funding rounds, often led by venture capital firms. These investment opportunities are not generally open to the public, and specific criteria are set by the company and its lead investors.
